Long term da­ta echo safe­ty pro­file of Gilead, Gala­pagos' po­ten­tial block­buster JAK in­hibitor

Ab­b­Vie’s land­mark FDA ap­proval for its po­ten­tial block­buster upadac­i­tinib — the re­place­ment for its cash cow Hu­mi­ra — came with a dread­ed black box warn­ing. Fil­go­tinib, Gilead and Gala­pa­gos’ ri­val JAK drug, is be­ing primed for US re­view but in­vestors are ner­vous it too will suf­fer the same fate. On Fri­day, the com­pa­nies said 52-week da­ta from twin late-stage stud­ies re­in­forced the safe­ty, tol­er­a­bil­i­ty and ef­fi­ca­cy pro­file of the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER